ATLANTA, Oct. 14 /PRNewswire-FirstCall/ -- CryoLife, Inc.
(NYSE: CRY), an implantable biological medical device and
cardiovascular tissue processing company, announced today that 2010
third quarter financial results will be released on Thursday, November 4, 2010. On that day,
the Company will hold a teleconference call and live webcast at
10:00 a.m. Eastern Time to discuss
the results, followed by a question and answer session hosted by
Steven G. Anderson, president and
chief executive officer of CryoLife, Inc.
To listen to the live teleconference, please dial 201-689-8261 a
few minutes prior to 10:00 a.m.
A replay of the teleconference will be available November 4 through November 11 and can be
accessed by calling (toll free) 877-660-6853 or 201-612-7415.
The account number for the replay is 244 and the conference
number is 359197.
The live webcast and replay can be accessed by going to the
Investor Relations section of the CryoLife web site at
www.cryolife.com and selecting the heading Webcasts &
Presentations.
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing
and distribution of implantable living human tissues for use in
cardiac and vascular surgeries throughout the U.S. and Canada. The Company's CryoValve® SG
pulmonary heart valve, processed using CryoLife's proprietary
SynerGraft® technology, has FDA 510(k) clearance for the
replacement of diseased, damaged, malformed, or malfunctioning
native or prosthetic pulmonary valves. The Company's
CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for
the repair or reconstruction of the right ventricular outflow tract
(RVOT), which is a surgery commonly performed in children with
congenital heart defects, such as Tetralogy of Fallot, Truncus
Arteriosus, and Pulmonary Atresia. CryoPatch SG is
distributed in three anatomic configurations: pulmonary
hemi-artery, pulmonary trunk, and pulmonary branch. The
Company's BioGlue® Surgical Adhesive is FDA approved as an adjunct
to sutures and staples for use in adult patients in open surgical
repair of large vessels. BioGlue is also CE marked in the
European Community and approved in Canada and Australia for use in soft tissue repair and
was recently approved in Japan for
use in the repair of aortic dissections. The Company's
BioFoam™ Surgical Matrix is CE marked in the European Community for
use as an adjunct in the sealing of abdominal parenchymal tissues
(liver and spleen) when cessation of bleeding by ligature or other
conventional methods is ineffective or impractical. In late
September, CryoLife entered into a distribution agreement for
PerClot®, an absorbable powder hemostat that has CE Mark
designation allowing commercial distribution into the European
Community. CryoLife currently distributes HemoStase®, a
hemostatic agent, in much of the U.S. for use in cardiac and
vascular surgery and in many international markets for cardiac,
vascular, and general surgery, subject to certain exclusions,
although CryoLife has received notice from Medafor, Inc. that it
has terminated its HemoStase distribution agreement with CryoLife.
For additional information about the company, visit CryoLife's
Web site: http://www.cryolife.com.
Media Contact:
|
|
|
|
D. Ashley Lee
|
|
Executive Vice President, Chief
Financial Officer and
|
|
Chief Operating
Officer
|
|
Phone: 770-419-3355
|
|
|
SOURCE CryoLife, Inc.
Copyright . 14 PR Newswire